ClinicalTrials.gg
Sign In
Status unknownNCT02306083Updated May 8, 2015

Effect of Glucosamine on Intraocular Pressure

A Phase 3 interventional study of Placebo three times a day and glucosamine sulfate 1500 mg three times a day in Intraocular Pressure Changes After Glucosamine Sulfate Consumption., sponsored by Shahid Beheshti University of Medical Sciences. Status unknown at 1 site in Iran. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-05-08.

Sponsored by Shahid Beheshti University of Medical Sciences · Phase 3, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Mar 2014), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 3
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Study summary

In this double blind clinical trial 92 patients suffering from rheumatoid arthritis are included. Those with the history of intraocular and corneal surgery, diabetic and heavy smokers are excluded from the study. Before starting the treatment all patients undergo complete ophthalmic exam, corneal biomechanical properties assessment by Ocular Response Analyzer (ORA) and corneal thickness measurement. Patients are randomly assigned to treatment and placebo groups. Those in the treatment groups receive glucosamine sulfate 1500 mg three times a day. Those in placebo arm receive alike capsule with the same schedule. At month 3 and 6 IOP(intraocular pressure), ORA and pachymetry would be checked again.

02

Conditions studied

  • Intraocular Pressure Changes After Glucosamine Sulfate Consumption.
03

In context

Lead sponsor

Shahid Beheshti University of Medical Sciences is the lead sponsor of 229 studies on the registry; 19 are open to participants now.

Browse Shahid Beheshti University of Medical Sciences studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of rheumatoid arthritis based on ACR (American College of Rheumatology)FC(functional classes).
  • No history of using drugs tested in the study.

Exclusion criteria

Exclusion Criteria:

  • History of any kind of corneal surgery.
  • History of intraocular surgery.
  • History of diabetes mellitus.
  • Heavy smokers.
  • Unwillingness to participate in the study.
05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
41 participants (estimated)

Study arms

  • Placebo comparator
    Administration of the Placebo

    Placebo three times a day.

    Drug: Placebo three times a day

  • Placebo comparator
    Administration of the glucosamine sulfate

    glucosamine sulfate 1500 mg three times a day

    Drug: glucosamine sulfate 1500 mg three times a day

Interventions

  • DrugPlacebo three times a day

    Also known as: oral consumption

  • Drugglucosamine sulfate 1500 mg three times a day

    Also known as: oral consumption

06

What researchers measure

Primary outcomes

  1. Intraocular pressure changes

    : Goldmann applanation tonometry

    Time frame: until 6 months

Secondary outcomes

  1. corneal biomechanical changes

    Ocular Response Analyzer (ORA)

    Time frame: until 6 months

07

Study locations

1 of 1 sites recruiting
  • Islamic Republic OF Iran
    Tehran, Iran
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2014 and a primary completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2014
First posted
Dec 3, 2014
Start
Jul 2014
Primary completionEst.
Jun 2015
Last update
May 8, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02306083
Lead sponsor
Shahid Beheshti University of Medical Sciences
Responsible party
Zahra Rabbani Khah (clinical professor ,ophthalmic research center, Shahid Beheshti University of Medical Sciences) — Principal investigator
First posted
Dec 3, 2014
Start date
Jul 2014
Primary completion
Jun 2015 (estimated)
Last update
May 8, 2015

Study contacts

Mohammad Pakravan, MD
Contact
labbafi@hotmail.com
009822591616

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Shahid Beheshti University of Medical Sciences →

Start the discussion